View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 7, 2019

Neurocrine reports positive long-term data for Ingrezza

Neurocrine Biosciences has reported positive results from pooled analyses of the long-term effects of Ingrezza (valbenazine) in decreasing abnormal movements in tardive dyskinesia (TD) disorder.

Neurocrine Biosciences has reported positive results from pooled analyses of the long-term effects of Ingrezza (valbenazine) in decreasing abnormal movements in tardive dyskinesia (TD) disorder.

TD is characterised by persistent involuntary movements of the face, torso and/or other body parts.

Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor intended to minimise the amount of dopamine in a brain region that regulates movement and motor function.

It has US Food and Drug Administration (FDA) approval to treat adults suffering from TD.

Pooled analyses from the Phase III KINECT 3 and KINECT 4 trials showed that a once-daily 40mg dose of the drug led to a response on the Abnormal Involuntary Movement Scale (AIMS) scale in 53.7% of patients treated for 48 weeks.

Ingrezza also demonstrated a Clinical Global Impression of Change-Tardive Dyskinesia (CGI-TD) response in 65.5% of patients.

In addition, data from the Phase III KINECT 3 trial revealed early response following two weeks of therapy with a 40mg or 80mg dose in 50% of participants.

Irrespective of the response at two weeks, meaningful reductions in the disorder were observed with long-term treatment.

According to the data, the drug was generally well-tolerated without any new safety concerns or notable worsening of psychiatric symptoms.

Neurocrine Biosciences chief medical officer Eiry Roberts said: “The analyses of pooled data continue to support the growing body of evidence that Ingrezza is an effective treatment for the long-term management of tardive dyskinesia.

“It is important to choose the best dosing option of Ingrezza and continue treatment to achieve long-term outcomes as tardive dyskinesia varies from patient to patient as well as their treatment response.”

The Phase III KINECT 3 and KINECT 4 studies were conducted in 234 and 163 moderate to severe TD patients, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena